Last reviewed · How we verify

Hyperpolarized Xe129 — Competitive Intelligence Brief

Hyperpolarized Xe129 (Hyperpolarized Xe129) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Area: Oncology.

phase 2 Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Hyperpolarized Xe129 (Hyperpolarized Xe129) — Mario Castro, MD, MPH. Hyperpolarized Xe129 is a magnetic resonance imaging (MRI) contrast agent that enhances the visibility of tumors and other lesions.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Hyperpolarized Xe129 TARGET Hyperpolarized Xe129 Mario Castro, MD, MPH phase 2

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape

No sponsor landscape data.

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Hyperpolarized Xe129 — Competitive Intelligence Brief. https://druglandscape.com/ci/hyperpolarized-xe129. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: